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Abstract
Although recurrent somatic mutations in the splicing factor U2AF1 (also known as U2AF35) have been identified in multiple
cancer types, the effects of these mutations on the cancer transcriptome have yet to be fully elucidated. Here, we identified
splicing alterations associated with U2AF1 mutations across distinct cancers using DNA and RNA sequencing data from The
Cancer Genome Atlas (TCGA). Using RNA-Seq data from 182 lung adenocarcinomas and 167 acute myeloid leukemias (AML),
in which U2AF1 is somatically mutated in 3–4% of cases, we identified 131 and 369 splicing alterations, respectively, that
were significantly associated with U2AF1 mutation. Of these, 30 splicing alterations were statistically significant in both lung
adenocarcinoma and AML, including three genes in the Cancer Gene Census, CTNNB1, CHCHD7, and PICALM. Cell line
experiments expressing U2AF1 S34F in HeLa cells and in 293T cells provide further support that these altered splicing events
are caused by U2AF1 mutation. Consistent with the function of U2AF1 in 39 splice site recognition, we found that S34F/Y
mutations cause preferences for CAG over UAG 39 splice site sequences. This report demonstrates consistent effects of
U2AF1 mutation on splicing in distinct cancer cell types.
Citation: Brooks AN, Choi PS, de Waal L, Sharifnia T, Imielinski M, et al. (2014) A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic
Mutations in U2AF1 Reveals Commonly Altered Splicing Events. PLoS ONE 9(1): e87361. doi:10.1371/journal.pone.0087361
Editor: Gil Ast, Tel Aviv University, Israel
Received June 28, 2013; Accepted December 20, 2013; Published January 31, 2014
Copyright:  2014 Brooks et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a National Institutes of Health Grant 5U24CA143867-03. ANB is a Merck Fellow of the Damon Runyon Cancer Research
Foundation (DRG-2138-12). JC is supported by an American Cancer Society AstraZeneca Postdoctoral Fellowship. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: matthew_meyerson@dfci.harvard.edu
Introduction
Recent whole-exome sequencing studies have identified recur-
rent somatic mutations in splicing factors in myelodysplastic
syndromes [1], chronic lymphocytic leukemia [2], acute myeloid
leukemia [3], breast cancer [4], lung adenocarcinoma [5], and
uveal melanoma [6]. Many of these mutated splicing factors are
branch point or 39 splice site recognition factors (e.g., SF3B1 and
U2AF1) and are involved in regulating intron removal from pre-
mRNA. The 39 splice site recognition complex is composed of
U2AF1 and U2AF2 (also known as U2AF65), where U2AF1 is
important for the recognition of the AG at 39 splice sites [7] and
U2AF2 recognizes the polypyrimidine tract upstream of the AG
[8].
U2AF1 has been reported to have significant hotspot mutations
at amino acid position 34 in myelodysplastic syndromes [1], lung
adenocarcinomas [5], and AML [3]. U2AF1 mutations co-occur
with mutations in known driver oncogenes in lung adenocarcino-
ma [5] and it is yet unclear if these mutations are oncogenically
transforming. To further elucidate core effects of U2AF1 mutations
on cancer biology, we aimed to identify common transcriptome
alterations associated with U2AF1 mutations in distinct cancer
types.
Results
Somatic mutations in U2AF1 across 12 cancer types
To look at transcriptome changes associated with U2AF1
mutations in different cancer types, we used The Cancer Genome
Atlas (TCGA) data that provide both somatic mutations at the
DNA level and high-throughput sequencing of mRNA (RNA-Seq)
in the same individual specimens across multiple cancer types.
Using available data from 12 TCGA cancer types [9], we
identified cancer harboring somatic mutations in U2AF1. Across
2,979 cancer specimens with both whole-exome sequencing and
RNA-Seq, 26 had missense mutations in U2AF1—17 at amino
acid position 34 (Table S1 in Document S1, Figure 1). U2AF1
S34F mutations were found in eight lung adenocarcinomas (4%),
four AML samples (2%), two endometrial carcinomas (1%), and
one bladder cancer sample (1%). There were also two U2AF1
S34Y AML samples (1%). U2AF1 was reported to be significantly
mutated in both lung adenocarcinomas [5] and AML [3];
however, not significantly mutated in endometrial carcinomas
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In addition to S34F/Y mutations, eight other somatic mutations
were observed in U2AF1. To identify transcriptome alterations
associated with U2AF1 mutation, we focused on lung adenocar-
cinoma and AML as these cancer types have a higher frequency of
mutations and thus would have more power to detect statistically
significant changes associated with the mutation and control for
differences between tissue of origin. The S34F and S34Y
mutations result in aromatic amino acids; therefore, we consider
S34F and S34Y mutations to be functionally similar.
Transcriptome alterations associated with U2AF1 S34F/Y
mutations in lung adenocarcinoma and acute myeloid
leukemia
We used JuncBASE [11] to identify alternative splicing events
that were significantly differentially spliced between U2AF1 wild-
type cancer samples and U2AF1 S34F/Y samples. JuncBASE
identifies and classifies forms of alternative splicing (e.g., cassette
exon, alternative 59 splice sites, alternative 39 splice sites),
quantifies the abundance of the inclusion or exclusion of each
alternative exon, then calculates a ‘‘percent spliced in’’ (PSI) value
for each splicing event in each cancer sample. A Wilcoxon rank-
sum test was performed on PSI values between cancers with or
without U2AF1 S34F/Y mutations to identify splicing events that
were significantly different between the two groups. To control for
tissue of origin, we compared U2AF1 wild-type and S34F/Y
samples within the same cancer type. The U2AF1 S34F lung
adenocarcinomas were found across the three expression subtypes
(TCGA, submitted) and the U2AF1 S34F/Y AML specimens
occurred across five French-America-British (FAB) AML subtypes
[3]; therefore, we did not further control for subtype. Somatic
mutations in U2AF1 have been found to be mutually exclusive
with other splicing factors [1,3,5], suggesting that spliceosome
pathway mutations may have the same functional effect on
oncogenesis. To remove potential confounders from mutations in
other splicing factors, we looked for differentially spliced events
between samples with U2AF1 S34F/Y mutation and samples







Figure 1. Splicing changes associated with U2AF1 S34F/Y mutation in lung adenocarcinoma and AML. (A) Representation of somatic
mutations in U2AF1 observed across 12 TCGA cancer types [9]. Five cancer types had no somatic mutations in U2AF1. Amino acid positions are
indicated. Zn, zinc finger; UHM, U2AF homology motif. (B) JuncBASE analysis of RNA-Seq data identified 131 and 369 splicing events significantly
differentially spliced in lung adenocarcinoma and AML specimens bearing U2AF1 S34F/Y mutations, respectively.
doi:10.1371/journal.pone.0087361.g001
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S1–S2 in Document S1).
Using JuncBASE, we identified 131 and 369 alternative splicing
events that were significantly differentially spliced in the presence
of a U2AF1 S34F/Y mutation in lung adenocarcinoma and AML
(False Discovery Rate (FDR),5%), respectively. Additionally,
these splicing events have a .10% difference in the median PSI of
cancers with no splicing factor gene mutation and cancers with
U2AF1 S34F/Y mutations (File S1–S3). Comparing U2AF1 S34F/
Y mutation with U2AF1 wild-type samples (some with mutations
in other splicing factors) yielded similar results in lung adenocar-
cinoma (TCGA, submitted) and AML (File S4). JuncBASE
quantification of U2AF1 S34F/Y-associated splicing events in
AML were consistent with an analysis of U2AF1 mutations in 20
AML samples [12](r
2=0.84, Figure S1 in Document S1).
As both a positive and negative control for this analysis, we
compared 10 lung adenocarcinoma samples with a MET exon 14
splice site mutation or deletion with all other lung adenocarcinoma
samples to look for significant differential splicing between the two
groups. The MET exon 14 alterations occur at a similar frequency
as U2AF1 mutations in lung adenocarcinoma (TCGA, submitted).
This analysis serves as a positive control, because the most strongly
associated differential splicing event should be MET exon 14. This
analysis also serves as a negative control as the alterations would
not be expected to cause global changes in splicing since the
mutations occur at cis-acting splice site alterations. Indeed,
JuncBASE analysis only identified the splicing of MET exon 14
as significantly differentially spliced with a difference in PSI .
10%.
As an additional control, we identified alternative splicing events
significantly associated with STAG2 mutations in lung adenocar-
cinoma and AML, as STAG2 is not expected to be a splicing
regulator and it is mutated at a similar frequency in both cancer
types. Only one splicing event was significantly associated with
STAG2 mutation in lung adenocarcinoma and none in AML.
Similar to what was observed in a comprehensive character-
ization of lung adenocarcinoma (TCGA, submitted), the splicing
events associated with U2AF1 S34F mutations in AML also show
enrichment of cassette exons and alternative 39 splice sites
(Figure 1B). We do not observe broad effects on intron retention,
which is thought to occur in the presence of a spliceosome
mutation. If U2AF1 mutations cause many introns to be unspliced,
perhaps it is not in a consistent manner and those instances are
cleared away by nonsense-mediated decay (NMD). To see if the
cassette exon and 39 splice site bias is a general feature of
alternative splicing in these cancer types or specific to splicing
altered by U2AF1 mutation, we identified the proportions of each
type of alternative splicing event in the top 10% most highly
variable splicing events in lung adenocarcinomas without splicing
factor mutations (Figure S2 in Document S1). U2AF1 S34F/Y
cancers preferentially exhibit alterations in cassette exon and 39
splice sites compared to the set of highly variable splicing events
(chi-squared test, P=6.6e-26).
Although there are splicing changes that are associated with
U2AF1 S34F/Y mutation in these cancer specimens, it is unclear if
the splicing changes are caused by the mutation or if there are
unknown genomic alterations that are also correlating with the
splicing changes. To evaluate further the relationship between the
splicing changes and U2AF1 S34F mutations, we analyzed
previously published RNA-Seq data comparing ectopic expression
of U2AF1 S34F or U2AF1 wild-type expression in HeLa cells [1].
JuncBASE analysis comparing no-induction controls with U2AF1
wild-type or U2AF1 S34F induction identified 1,221 and 5,399
significant splicing changes, respectively (File S5 and S6). We find
a significant overlap of 165 splicing changes upon induction of
U2AF1 S34F in HeLa cells and splicing changes in human cancers
with U2AF1 S34F/Y mutations (Figure 2, Fisher’s exact test, P,
2.2e-16). In contrast, we find a smaller proportion of splicing
changes upon U2AF1 wild-type induction to be similar to
alterations in human cancers (15/1221, Fisher’s exact test,
P=0.72). In total, 35% of the U2AF1 S34F/Y-associated splicing
changes seen in lung adenocarcinoma or AML are supported by
splicing changes caused by U2AF1 S34F expression in HeLa cells.
We would not expect all splicing changes to be observed in the
HeLa cell experiments as splicing changes are known to be context
dependent (reviewed in [13]) and U2AF1 induction causes
overexpression of the gene [1], which may affect spliceosome
complex formation.
U2AF1 S34F/Y preferentially splices to CAG rather than
UAG 39 splice site sequences
U2AF1 is the small subunit of the U2AF heterodimer that
recognizes the AG consensus of 39 splice sites. A previous study
that identified differential splicing of 35 exons associated with
U2AF1 mutation identified a sequence signature at 39 splice sites of
the alternative exons [12]. Given the significant changes in cassette
exons and alternative 39 splice site events associated with U2AF1
S34F/Y mutation, we examined the sequences of 39 splice sites
that were preferentially used in U2AF1 S34F/Y mutated cancers.
For simplicity, we only examined splicing changes between two
alternate 39 splice sites.
As splicing factor binding can differ depending on splicing
activation or repression (reviewed in [14]), we looked at splice site
sequences of exon inclusion and exclusion events, separately. From
the set of U2AF1 S34F/Y-associated cassette exons and alternative
39 splice site changes in AML, we found a significant bias toward
skipping of an exon (69% of cassette exons) or usage of a more
distal 39 splice site (75% of alternative 39 splice sites) (binomial test,
P,1e-4, Figure 3A). We found a similar bias toward exon skipping
and distal splice site usage of U2AF1 S34F-associated splicing
events in lung adenocarcinoma (Figure S3 in Document S1). As a
comparison, we identified alternative splicing events significantly
associated with RBM10 mutation in lung adenocarcinoma (File
S7). The RNA binding protein RBM10 was found to be
significantly mutated in lung adenocarcinomas with recurring
frameshift, nonsense, or splice site mutations [5]. The observed
exon skipping is specific to U2AF1 S34F-associated splicing events
Figure 2. Commonly altered splicing events associated with
U2AF1 mutation in lung adenocarcinoma and AML. A comparison
of changes in splicing associated with U2AF1 somatic mutation in
human cancers and U2AF1 S34F induction in HeLa cells.
doi:10.1371/journal.pone.0087361.g002
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associated splicing events (Figure S4A–B in Document S1).
Consistent with previous findings [12], we found a trinucleotide
consensus TAG sequence at proximal 39 splice sites of skipped
cassette exons. Moreover, we also find this motif at proximal splice
sites of alternative 39 splice site events in U2AF1 S34F/Y AML
samples (Figure 3B). Additionally, a consensus CAG splice site at
the more distal 39 splice site is observed, which has not been
previously reported (Figure 3B). A similar preference of CAG
splice sites (with a minor AAG sequence) over TAG splice sites is
observed in exons preferentially included in U2AF1 S34F/Y AML
samples (Figure 3C). These preferential splice site sequence motifs
differ from splice site motifs observed near proximal and distal 39
splice sites of control alternative splicing events (Figure S4C in
Document S1, Wilcoxon rank-sum test, FDR .95%).
Strikingly, we see the same sequence preferences in cassette
exon and alternative 39 splice site changes in U2AF1 S34F lung
adenocarcinomas (Figure S3 in Document S1) and in HeLa cells
transduced with U2AF1 S34F mutant constructs (Figure S5A–B in
Document S1). Moreover, we do not see this consensus 39 splice
site sequence in RBM10 LOF-associated splicing in lung adeno-
carcinoma (Figure S4A–B in Document S1) nor in splicing
changes in HeLa cells transduced with wild-type U2AF1 (Figure
S5C–D in Document S1), supporting that the sequence preference











Figure 3. Sequence preferences at altered 39 splice sites associated with U2AF1 S34F/Y mutation. (A) Proportion of altered cassette exon
and alternative 39 splice site events that show exon skipping versus exon inclusion. (B) Consensus sequence motifs identified at the proximal (prox
39ss) and distal 39 splice sites (dist 39ss) of exon skipping events. (C) Consensus sequence motifs at the proximal and distal 39 splice sites of exon
inclusion events. Splicing changes of expressed and annotated 39 splice site choices where the splice site choice is TAG vs. CAG or TAG vs. AAG in (D)
HeLa cells+induced U2AF1 S34F or (E) HeLa cells+induced U2AF1 wild-type.
doi:10.1371/journal.pone.0087361.g003
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events that were strongly associated with U2AF1 mutation and do
not resolve sequence preferences between two splice site choices
from an individual splicing event. To further investigate the CAG
splice site preferences over UAG splice sites, we examined splice
site sequence switches between all pairs of expressed and
annotated CAG versus TAG 39 splice sites. Using a lowered
threshold for identifying splicing switches, we found that 57% of
CAG versus TAG 39 splice sites were altered in HeLa cells
expressing the U2AF1 S34F mutation, while 36% were altered
when expressing a U2AF1 wild-type construct (Figure 3D). Of
U2AF1 S34F-associated splice site switches, 83% (884/1,065) were
a TAG to a CAG splice site, while only 53% (347/660) switched
from a TAG to a CAG when expressing U2AF1 wild-type (Fisher’s
exact test, P,2.2e-16). A similar bias of switches from TAG to
AAG 39 splice sites was observed (Fisher’s exact test, P=2.518e-5,
Figure 3D).
Our analysis shows that the U2AF1 S34F/Y mutation causes
alterations in 39 splice site usage where a [C/A]AG 39 splice site is
preferred over a UAG splice site. We did not observe altered
splicing of all UAG 39 splice sites; however, it is difficult to
distinguish between unaltered splicing or degradation of the
aberrant transcript by nonsense-mediated decay, thus appearing to
be unchanged.
Transcriptome alterations in cell cycle genes and other
cancer genes are associated with U2AF1 mutation
Somatic mutation in U2AF1 may cause splicing changes of key
cancer genes, resulting in altered gene function or altered
pathways. To identify potential downstream biological conse-
quences of U2AF1 mutation, we performed a Gene Set
Enrichment Analysis (GSEA) [15,16] to identify gene sets
positively correlated with the U2AF1 S34F/Y mutation in lung
adenocarcinoma and in AML. No gene sets reached statistical
significance given an FDR cutoff of 25%. It was previously
reported that transduction of U2AF1 S34F mutations in HeLa cells
caused upregulation of components of the nonsense-mediated
decay (NMD) pathway [1]. We did not observe a significant
upregulation in expression of NMD factors associated with U2AF1
mutation in lung adenocarcinoma or AML.
Although no gene sets passed FDR significance, the top-two
enriched GO ontology gene sets in AML with the highest
normalized enrichment scores were ‘‘mitotitc cell cycle’’ and ‘‘M
phase of mitotic cell cycle’’ (Figure S6 in Document S1, nominal
P,0.05). A subset of these cell cycle genes were upregulated in
AML samples with U2AF1 S34F/Y mutation. Consistent with the
effect of U2AF1 mutation on the cell cycle, RNAi depletion of
U2AF1 [17] and U2AF1 S34F expression in HeLa cells [1] results
in an increased fraction of cells in G2/M phase. We do not see any
association with cell cycle gene sets in U2AF1 S34F lung
adenocarcinomas. This may be explained by the high normal
tissue contamination in this cancer type [18], which may affect
gene expression signatures.
In line with these observations, there are 31 genes with U2AF1
S34F/Y-associated splicing events represented in the ‘‘mitotic cell
cycle’’ and ‘‘M phase of mitotic cell cycle’’ gene sets, including
CHEK2, CDC27, and multiple subunits of the anaphase-promoting
complex (Table S3 in Document S1).
Splicing alterations associated with U2AF1 S34F/Y mutation in
both lung adenocarcinoma and AML are of particular interest as
these commonly altered genes may make core contributions to
selective advantage in these cancers. We found a significant
overlap of 30 altered splicing events that were associated with
U2AF1 S34F/Y mutations in both lung adenocarcinoma and
AML (Figure 2 and Table 1, Fisher’s exact test p,2.2e-16). For all
30 splicing events, the direction of splicing was the same in both
cancer types, where U2AF1 mutation caused a shift to exon
skipping or exon inclusion for the same splicing event. The
majority (63%) of the commonly altered events showed more distal
39 splice site usage in U2AF1 mutated samples. In addition, 17/30
splicing events were significantly affected upon induction of
U2AF1 S34F in HeLa cells but had no change upon induction
of U2AF1 wild-type (Table 1). 60% of these commonly altered
splicing events show 39 splice site sequence preference of a CAG,
or AAG, splice site over a TAG splice site (Table 1, a or b),
consistent with the overall observed splice site sequence preference
of U2AF1 S34F/Y-associated events. Additionally, we looked for
genes with altered splicing events that were also in the Cancer
Gene Census [19] (Table S4 in Document S1). Three Cancer
Gene Census genes were among the 30 commonly altered splicing
events and are of particular interest: CTNNB1 (TCGA, submitted),
CHCHD7, and PICALM (Table 1 and Table S4 in Document S1).
The altered splicing event in CTNNB1 in U2AF1 mutant cancers
results in a shift toward splicing of a more proximal splice site in
the 39 UTR of CTNNB1 (Figure 4A–B). Significant upregulation of
proximal splice site usage was also observed in HeLa cells
expressing U2AF1 S34F (Figure 4C). The upregulated isoform has
been shown to be a less stable mRNA in HeLa cells [20];
therefore, the altered splicing event may result in a reduction of
CTNNB1 protein levels. Although, CTNNB1 activation is a
canonical driver mutation, a decrease in normal levels of
CTNNB1 may also be advantageous to cancer cells as RNAi
depletion of CTNNB1 has been shown to increase cell migration
[21].
To further test experimentally whether the splicing events
observed in U2AF1 mutant cancers are directly caused by U2AF1
mutation, we transfected 293T cells with either U2AF1 wild-type
or U2AF1 S34F constructs and assayed changes in five splicing
events using quantitative RT-PCR (Figure 5, Figure S7 in
Document S1). We were able to validate changes in splicing in
CTNNB1, CHCHD7, and PTBP1 in cells transfected with U2AF1
S34F constructs and not in cells transfected with U2AF1 wild-type
(Figure 5, unpaired t-test, P,0.1). Splicing events in KARS and
CHEK2 did not validate and may be context dependent, false-
positives in the transcriptome analysis, false negatives in the
transfection experiment, or indirect delayed targets of U2AF1
activity.
Discussion
Our analysis of splicing and gene expression changes associated
with U2AF1 mutation across multiple cancer types has revealed
alterations in 39 splice site sequence recognition and highlights
potential biological consequences through altered cancer genes,
such as CTNNB1, PICALM, and CHCHD7. In addition, we have
validated that at least some of these splicing alterations are direct
consequences of U2AF1 mutation in transfection experiments.
Many factors are involved in correct splice site recognition in
complex with U2AF1, including U2AF2. It has been well know
that the 39 splice site consensus motif includes a C or U nucleotide
before the AG at the end of introns and mutations in U2AF1 give
the first indication that a factor has a specific preference for this 2
3 position [12]. U2AF1 has been shown to weakly bind to RNA
via it’s UHM domain [22]. Perhaps the S34F mutation in the
upstream zinc finger domain affects 39 splice site sequence
recognition via direct interaction with the pre-mRNA or through
protein-protein interactions with U2AF2, hnRNP A1 [23], or
DEK [24]. Further biochemical characterization of the U2AF1
Splicing Changes Due to Somatic U2AF1 Mutation
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general understanding of 39 splice site sequence recognition.
In summary, we found multiple genes including several known
cancer genes with altered splicing in the presence of the U2AF1
mutation both in human cancer and in U2AF1 mutant transfected
cells. The impact of these splicing alterations on gene function is
an important topic for future investigation. Our identification of
splicing changes significantly and consistently associated with
somatic mutations in the U2AF1 splicing factor highlights the need
for future study into the function of alternative splice forms of




Somatic mutation calls from the 12 TCGA Pan-Cancer cancer
types were used (doi:10.7303/syn1710680.4), with the exception of
lung adenocarcinoma. Lung adenocarcinoma somatic mutation
calls were taken from the TCGA lung adenocarcinoma analysis
working group (TCGA, submitted).
RNA-Seq processing
RNA-Seq alignment files for 230 lung adenocarcinomas and
173 acute myeloid leukemias (AML) were available through
CGHub (https://cghub.ucsc.edu). AML alignments downloaded
from CGHub used an older version of the human genome
reference (hg18); therefore, the AML BAM files were converted to
FASTQ using SamToFastq [25] and then realigned against hg19
using TopHat [26] with the following parameters: ‘‘-G [Gencode
v7 transcripts [27]] –mate-inner-dist 300 –mate-std-dev 500’’. One
AML sample failed RNA-Seq re-alignment and processing and
was excluded: TCGA-AB-2977. RNA-Seq alignments of lung
adenocarcinoma samples used MapSplice [28].
RNA-Seq FASTQ files from HeLa cell experiments were
downloaded from the DDBJ repository with the accession
Table 1. 30 significant splicing alterations associated with U2AF1 S34F/Y mutations in both lung adenocarcinoma and AML.
Gene AS type
Distal 39 splice
site usage? U2AF1 S34F HeLa?
Proximal splice
site Distal splice site Strand Splice site pref.
ACAD8 CE Y Y chr11:134126981 chr11:134128408 + a
C12orf11 CE Y Y chr12:27067512 chr12:27067062 2 a
C17orf45 A3S Y Y chr17:16342841 chr17:16342973;chr17:16342894 + c
CHCHD7 A3S Y Y chr8:57128947 chr8:57128991 + b
CTNNB1 A3S Y* chr3:41281150 chr3:41281309 + c
FAM60A CE Y chr12:31458058 chr12:31451159 2 c
FXR1 CE Y chr3:180693100 chr3:180693909 + c
GUSB CE Y Y chr7:65440059 chr7:65439692 2 c
HMGCR CE Y Y chr5:74650880 chr5:74651189 + c
KARS CE Y Y chr16:75678361 chr16:75675622 2 a
KIAA0182 A3S Y chr16:85696949 chr16:85696991 + a
MAP3K3 CE chr17:61712068 chr17:61723393 + c
MARK3 A3S Y chr14:103934369 chr14:103934417 + b
MR1 CE Y Y chr1:181021370 chr1:181022708 + a
NSUN2 CE Y chr5:6632091 chr5:6625783 2 a
PABPC4 CE Y chr1:40029595 chr1:40029414 2 b
PICALM A3S chr11:85693047 chr11:85693032 2 b
PPHLN1 CE Y Y chr12:42745686 chr12:42748962 + a
PPM1B ALE chr2:44457551 chr2:44459454 + b
PTBP1 CE Y chr19:805512 chr19:806407 + a
RIPK2 CE Y Y chr8:90775056 chr8:90777568 + b
SERF1B ALE Y chr5:69328141 chr5:69337350 + a
SERF1B ALE Y chr5:70203560 chr5:70212767 + a
SETD4 CE Y chr21:37429776 chr21:37429503 2 b
SETX CE Y chr9:135144877 chr9:135140373 2 c
STRAP CE Y chr12:16036474 chr12:16042861 + c
TMEM131 CE Y Y chr2:98411579 chr2:98410017 2 a
USP25 CE chr21:17222095 chr21:17236586 + c
USP33 A3S Y chr1:78187611 chr1:78187587 2 a
ZRANB2 CE chr1:71531436 chr1:71530821 2 c
CE, cassette exon; A3S, alternative 39 splice site; ALE, alternative last exon;
*, U2AF1 wild-type induction caused differential splicing, but in the opposite direction as U2AF1 S34F induction; Splice site preference in U2AF1 S34F/Y samples: a,
TAGRCAG; b, TAGRAAG; c, other.
doi:10.1371/journal.pone.0087361.t001
Splicing Changes Due to Somatic U2AF1 Mutation
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TopHat [26] using Gencode v7 [27] as a transcript guide.
Splicing analysis
Lung adenocarcinoma samples, AML samples, and samples
from the HeLa cell line experiments (HeLa+U2AF1 wild-type non-
induced, HeLa+U2AF1 S34F non-induced, HeLa+U2AF1 wild-
type induced, HeLa+U2AF1 S34F induced) were run through
JuncBASE v0.6 [11] as three separate analysis sets. For lung
adenocarcinoma and AML samples, the JuncBASE parameters
used to identify alternative splicing events and calculate ‘‘percent
spliced in’’ (PSI) values were the following: -c 2 -j [introns from
Gencode v7 [27]] –jcn_seq_len 88. For the HeLa cell experiments, the
JuncBASE parameters used were the following: -c 2.5 -j [introns from
Gencode v7 [27]] –jcn_seq_len 202. For lung adenocarcinoma,
Cufflinks [29] de novo transcript annotations were available to
incorporate potentially novel exons in the splicing analysis
(TCGA, submitted). UCSC knownGenes hg19 transcript annotation
was used to define annotated exons [30].
To identify U2AF1 S34F/Y-associated differential splicing
events in lung adenocarcinoma and AML, compareSampleSets.py of
the JuncBASE v0.6 package was used with the following
parameters: –thresh 10 –mt_correction BH –which_test Wilcoxon –
delta_thresh 5.0. Splicing events with a significant difference (FDR,
5%) in PSI values between samples with no spicing factor mutation
and samples with U2AF1 S34F/Y mutation were further filtered
for events with a difference in the median PSI greater than 10%.
To identify splicing events affected by expression of U2AF1 S34F
in HeLa cells, pairwise_fishers_test_getASEvents_w_reference.py was used
to compare inclusion and exclusion isoform read counts between
the HeLa+U2AF1 wild-type non-induced sequenced library and
HeLa+U2AF1 S34F-induced sequenced library with the following
parameters: –thresh 25 –min_dpsi_threshold 5.0 –method BH –sign_cut-
off 0.05. To identify splicing events specific to U2AF1 S34F
induction, the event could not also be significantly different
between the two controls or when comparing the U2AF1 wild-type
non-induced to U2AF1 wild-type induced. This last restriction was
imposed to distinguish splicing changes due to the S34F mutation
Figure 4. CTNNB1 39 UTR splicing associated with U2AF1 S34F/Y mutation in lung adenocarcinoma and AML. ‘‘Percent spliced in’’ (PSI)
values of the proximal 39 splice site of the CTNNB1 39 UTR splice event in (A) lung adenocarcinoma and (B) AML. (C) RNA-Seq read coverage of the 39
UTR event in HeLa cells with two U2AF1 non-induced controls, induction of U2AF1 wild-type, and induction of U2AF1 S34F.
doi:10.1371/journal.pone.0087361.g004
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39 UTR splicing event of CTNNB1, U2AF1 wild-type induction
caused a change in splicing but in the opposite direction as U2AF1
S34F induction. To be conservative, we consider a U2AF1 S34F-
affected splicing event that has any change upon U2AF1 wild-type
induction to be non-specific to the U2AF1 mutation; however, we
make note in Table 1 of the CTNNB1 event that also showed a
splicing change in U2AF1 wild-type induction but in the opposite
direction.
In cases where there are more than two alternatives for a
splicing event (e.g., three alternative 39 splice site choices), the most
significant differentially expressed isoform is reported.
To identify U2AF1 S34F/Y-associated differential splicing in
both lung adenocarcinoma and AML, we checked for overlap in
the genomic coordinates of the splice event from each cancer type.
We found 31 splicing events that occurred at the same genomic
location of the genes; however, the event in ASPH was not the
same splicing event upon manual review and was not included in
Table 1. To test for the significance of the 30 commonly altered
splicing events in lung adenocarcinoma and AML, we used a
Fisher’s exact test where the 262 table contained the number of
splicing events affected and unaffected by the U2AF1 S34F/Y
mutation in the two cancer types. Only splicing events that were
expressed in both cancer types were used in the 262 table.
The list of Cancer Gene Census [19] genes were downloaded on
May 31, 2013 to compare against the list of U2AF1 S34F/Y-
associated splicing events.
39 splice site consensus sequences
The splice site sequence analysis used U2AF1 S34F/Y-
associated differentially spliced cassette exons and alternative 39
splice sites where only two alternate splice sites were observed from
the RNA-Seq data. The direction of splicing (exon inclusion or
skipping) was determined by taking the difference in the median
PSI value between samples with no splicing factor mutation and
samples with a U2AF1 S34F/Y mutation. For example, if the
median PSI was lower in the U2AF1 mutated samples, the
alternative exon was preferentially skipped in the presence of the
mutation.
39 splice site sequences from the proximal and distal splice sites
of each splicing event were extracted from genomic coordinates by
taking 20 nt upstream and 3 nt downstream of the intron/exon
boundary. Splice site sequences were used as input to WebLogo 3
[31,32] to generate consensus motif logos. Motif logos were only
generated for cases with 10 or more exon inclusion or exclusion
events.
Sequence preference at 39 splice sites
Cassette exon and alternative 39 splice site events involving only
annotated introns from Gencode v7 [27] were used to further
examine 39 splice site sequence preferences of U2AF1 S34F when
expressed in HeLa cells. Splicing events that were detectable with
at least 25 reads and had only two splice site choices were
considered. To look more globally at splicing switches, we used a
lower threshold of a change in PSI .5%, no statistical cutoff, and
no consideration of inclusion or exclusion of an alternative region,
as our criteria for calling a splicing switch. HeLa cells expressing
U2AF1 S34F or U2AF1 wild-type were compared to their
matched non-induced controls to determine if a splicing switch
occurred.
Gene Set Enrichment Analysis (GSEA)
Gene expression quantification from RNA-Seq data was taken
from the TCGA lung adenocarcinoma study (TCGA, submitted)
and from the TCGA Pan-Cancer Analysis Group for AML
samples (doi:10.7303/syn1681084.1). Gene expression for both
sets were given as RSEM values [33] and were pre-filtered before
performing Gene Set Enrichment Analysis (GSEA) analysis
Figure 5. Quantitative RT-PCR validation of splicing events
affected by expression of U2AF1 S34F in 293T cells. A fold
difference between total gene expression and the inclusion isoform of
each splicing event was normalized by the fold difference of a no-
transfection control sample to yield a relative inclusion level for each
sample. The genomic coordinates of tested splice events in (A) CTNNB1,
(B) CHCHD7, and (C) PTBP1 are given in Table 1.
doi:10.1371/journal.pone.0087361.g005
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unexpressed genes (RSEM values,0) and genes with low variance
(fold change between the minimum and maximum value .1.5).
The GO annotation database (c5.bp.v3.1.symbols.gmt) and the set
of nonsense-mediated decay (NMD) factors listed in Yoshida et al.
2011 [1] were used as gene set inputs to GSEA. Significance was
derived from 10,000 permutations of the phenotypes U2AF1
S34F/Y vs wild-type.
Data visualization
Plots comparing PSI values in samples with no splicing factor
mutation to samples with U2AF1 S34F/Y samples were created
with the ggplot2 (ggplot2.org) library in R [34]. RNA-Seq coverage
plots were generated by converting BAM files to bigWig files using
samtools [25], the wiggles script from TopHat [26], wigToBigWig
[30], and visualized using the UCSC genome browser (http://
genome.ucsc.edu) [30].
Validation experiments in 293T cells
293T cells were transfected with V5 tagged U2AF1 WT or
U2AF1 S34F constructs in biological triplicate and expression was
confirmed by western blot (Figure S7 in Document S1).
Quantitatitve RT-PCR was performed using Taqman Universal
PCR Master Mix (Life Technologies) on cDNA from non-
transfected and transfected samples. Taqman primers and probes
for five splicing events were selected for constitutive regions of
each gene to detect changes in total isoform expression and also
selected for a splice junction specific to the inclusion isoform
(Table S5 in Document S1). Custom probe sets were designed
using the Custom TaqMan Assay Design Tool (Life Technologies)
when necessary. Assays were run on the ABI 7300 Real-Time
PCR System under standard conditions. The fold difference
between the inclusion isoform and total gene expression was
calculated for each sample as 2
2(Ct(inclusion)-Ct(total)). Fold differences
were than normalized by the median fold difference observed in
non-transfected samples to get a relative inclusion level for each
splicing event.
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